WHO Pharmaceuticals Newsletter (No.6, 2012).

contenido


Regulatory Matters

Agomelatine ............................................................................................... 4

Denosumab ................................................................................................ 4

Intravenous 0.18% saline/4% glucose solution (‘hypotonic saline’) in

children ...................................................................................................... 5

Ondansetron ............................................................................................... 5

Proton Pump Inhibitors and Methotrexate ..................................................... 6



Safety of medicines

Dabigatran etexilate mesylate ...................................................................... 7

Human papillomavirus vaccine (Cervarix) ..................................................... 7

Non-steroidal anti-inflammatory drugs (NSAIDs) .......................................... 7

Over-The-Counter Eye Drops and Nasal Sprays ........................................... 8

Simvastatin ................................................................................................. 8


Signal

Ethinylestradiol/Drospirenone and Spinal cord infarction ................................. 10

Fesoterodine – GI haemorrhage .................................................................... 11



disponible en

http://bit.ly/UmybiI